Neo/adjuvant immunotherapy in the treatment of non‑small cell lung cancer
Authors:
Martin Svatoň 1; Jiří Blažek 1; Marcela Burešová 1; Josef Vodička 1
Authors‘ workplace:
Klinika pneumologie a ftizeologie, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň, Univerzita Karlova v Praze, Plzeň
1; Chirurgická klinika, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň, Univerzita Karlova v Praze, Plzeň
2
Published in:
Vnitř Lék 2022; 68(4): 217-220
Category:
Main Topic
Overview
Despite improvements in staging, surgical techniques, and the introduction of adjuvant chemotherapy for stage II and III nonsmall cell lung cancer (NSCLC), a large number of operated patients have recurrences of the disease. Due to the breakthrough results of immunotherapy in advanced stages of NSCLC, studies examining its potential benefits in operated patients were logically started. The first studies looked at the use of adjuvant immunotherapy after chemotherapy, where they had already shown the benefits of atezolizumab in a phase III study. A press release on positive data for pembrolizumab in the same indication has also been published recently. This was followed by studies with neoadjuvant immunotherapy, which in the phase III trials mostly switched to the chemoimmunotherapy regimen (with possible continuation of immunotherapy in adjuvant administration). Recently, there was a press release on the positive results of nivolumab with neoadjuvant chemotherapy. It is therefore highly likely that these treatment modalities will translate into standard treatment regimens in the near future.
Keywords:
neoadjuvant therapy – immunotherapy – adjuvant therapy – NSCLC
Sources
1. Felip E, Altorki N, Zhou C et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB‑ IIIA non‑small‑ cell lung cancer (IMpower010): a randomised, multicentre, open‑ label, phase 3 trial. Lancet. 2021;398(10308):1344-1357.
2. Friedlaender A, Naidoo J, Banna GL et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022;104:102350.
3. Desage AL, Bouleftour W, Tiffet O et al. Use of adjuvant chemotherapy in resected non‑small cell lung cancer in real‑ life practice: a systematic review of literature. Transl Lung Cancer Res. 2021;10(12):4643-4665.
4. Wu YL, Tsuboi M, He J et al. Osimertinib in Resected EGFR‑Mutated Non‑Small‑Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723.
5. Catania C, Muthusamy B, Spitaleri G et al. The new era of immune checkpoint inhibition and target therapy in early‑stage non‑small cell lung cancer. A review of the literature. Clin Lung Cancer 2021;S1525-7304(21)00279-5.
6. Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non‑small cell lung cancer: State of the art. Cancer Commun (Lond). 2021;41(4):287-302.
7. Chaft JE, Rimner A, Weder W et al. Evolution of systemic therapy for stages I‑ III non‑metastatic non‑small‑ cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547-557.
8. Ahern E, Solomon BJ, Hui R et al. Neoadjuvant immunotherapy for non‑small cell lung cancer: right drugs, right patient, right time? J Immunother Cancer. 2021;9(6):e002248.
9. Tisková zpráva firmy Merck. Dostupné na: https://www.merck.com/news/mercks‑keytruda‑pembrolizumab‑showed‑statistically‑significant‑improvement‑in‑disease‑free‑survival‑versus‑placebo ‑as‑adjuvant‑treatment‑for‑patients‑with‑stage‑ib‑iiia‑non‑small‑cell/
10. Chmielewska I, Stencel K, Kalinka E et al. Neoadjuvant and Adjuvant Immunotherapy in Non‑Small Cell Lung Cancer‑Clinical Trials Experience. Cancers (Basel). 2021;13(20):5048.
11. Szeto CH, Shalata W, Yakobson A et al. Neoadjuvant and Adjuvant Immunotherapy in Early‑Stage Non‑Small‑Cell Lung Cancer, Past, Present, and Future. J Clin Med. 2021; 10(23):5614.
12. Cascone T, William WN Jr, Weissferdt et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non‑small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504-514.
13. Spicer J, Wang CH, Tanaka F et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum‑doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non‑small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2021;39:15_suppl, 8503-8503
14. Tiskové prohlášení firmy BMS. Dostupné na: https://news.bms.com/news/corporate‑financial/ 2021/Neoadjuvant‑Opdivo‑nivolumab‑Plus‑Chemotherapy‑Significantly‑Improves‑Event‑Free‑Survival‑in‑Patients‑with‑Resecta ble‑Non‑Small‑Cell‑Lung‑Cancer‑in‑Phase- 3-CheckMate--816-Trial/default.aspx
15. Deng H, Zhao Y, Cai X et al. PD‑L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early‑stage Non‑small cell lung cancer: A systematic review and meta‑analysis. Crit Rev Oncol Hematol. 2022; 170:103582.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 4
Most read in this issue
- Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease – where they are effective and where they are not
- Acetylsalicylic acid in primary prevention of cardiovascular disease
- COVID-19 and post-COVID – Jekyll and Hyde of modern medicine
- Acute kidney injury due to antimicrobial therapy